Hikma appoints Tobias Hestler as a Director

London, 6 August 2026 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) (Hikma) announces the appointment of Tobias Hestler as an independent Non-Executive Director with effect from 7 August 2026. Tobias will also be appointed a member of the Audit, Remuneration and Nomination and Governance Committees with effect from 7 August 2026.

Commenting on the appointment, Victoria Hull, Chair said "I am thrilled to welcome Tobias to the Hikma Board. Tobias is a transformation and growth-oriented former FTSE 100 CFO, bringing extensive financial leadership, strategic thinking, M&A, capital markets, and healthcare sector experience to the Board".

As part of Hikma's Board succession planning, Tobias will be appointed as Chair of the Audit Committee, succeeding Douglas Hurt, who will step down from that role, following the conclusion of the 2027 AGM.

About Tobias Hestler

Tobias was Group Chief Financial Officer and Executive Director of Haleon PLC from its listing as an independent FTSE 100 company in 2022 until 2024, having previously served as CFO designate of Haleon and CFO of GSK PLC's Consumer Healthcare Joint Ventures. Earlier in his career, Tobias held senior finance leadership roles at Novartis, including CFO of Sandoz, Novartis Consumer Health and Hexal AG.

Tobias is currently a Non-Executive Director of Convatec Group PLC, Non-Executive Director and Audit Committee Chair of Alliance Pharma Limited, Advisory Board Member of Aristo Pharma GmbH and Treasurer and Trustee of the Elton John AIDS Foundation.

Enquiries:

Hikma Pharmaceuticals PLC

Susan Ringdal: EVP, Strategic Planning and Global Affairs +44 (0) 20 7399 2760

Helen Middlemist, Group Company Secretary +44 (0) 20 7399 2760

This announcement is made in accordance with UK Listing Rule 6.4.6. There is no further information to be disclosed under the requirements of UK Listing Rule 6.4.8 of the UK Listing Rules in relation to Tobias Hestler's appointment.

About Hikma:

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB/stable S&P and BBB/stable Fitch)